According to an EU source, Novavax will begin distributing COVID-19 vaccinations to the European Union in the first quarter of 2022, as specialists from the region’s drug regulator gathered on Monday to determine whether to approve the injection.
The EU Commission had no quick reaction, and the biotech business in the United States was not immediately accessible for comment. Because they were not authorized to speak to the media, the EU source declined to be identified.
If authorized, the two-dose vaccination, Nuvaxovid, would be the sixth coronavirus shot to be introduced to the EU market as the Omicron coronavirus variety spreads.
Earlier this year, Novavax informed the European Union that it expected to begin sending limited shipments of its vaccine to the union by the end of this year, with the bulk of supply arriving in 2022, according to an EU official quoted by Reuters in May.
In August, the EU Commission and the business inked a deal for the delivery of up to 200 million pills, half of which are voluntary.